Applied Exomics announces new one-stop sequencing and data analytics services in collaboration with Source Bio
Published on 18 Oct 2021
Exploristics wins Innovate UK award
Published on 7 Oct 2021
TCR² therapeutics presents preclinical data on IL-15 enhanced TRUCS at AACR virtual special conference on tumor immunology & immunotherapy
Published on 5 Oct 2021
Gyroscope Therapeutics Announces Presentation of Positive Interim Phase I/II Data for Investigational Gene Therapy GT005 at Retina Society Annual Scientific Meeting
Published on 30 Sep 2021
Quell Therapeutics significantly expands clinical manufacturing capacity for its Engineered Treg Cell Therapies through a collaboration with the Cell and Gene Therapy Catapult
Published on 23 Sep 2021
Dr John Brown, CBE to retire as Cell and Gene Therapy Catapult’s Chairman
Published on 22 Sep 2021
TCR² Therapeutics announces positive interim results from ongoing phase 1/2 trial of gavo-cel for treatment refractory mesothelin-expressing solid tumors
Published on 17 Sep 2021
Autolus Therapeutics provides an update on its manufacturing facility in Stevenage
Published on 16 Sep 2021
Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis
Published on 13 Sep 2021

Peptinnovate announces change of name to Immune Regulation, strengthening of the Board and successful fundraise

Read the article
The appointment of these three experienced industry executives will bring valuable insight and resource to our Board and executive team. With their skills in immunology, clinical therapeutic development and strategy we have the expertise to advance our clinical programmes and look forward to the next stage of our progress.
Prof. Clive Page
Chairman of Immune Regulation
Freeline Announces Orphan Drug Designations for FLT201 for the Treatment of Gaucher Disease
Published on 9 Sep 2021
TCR² Therapeutics receives FDA orphan drug designation for gavo-cel for the treatment of cholangiocarcinoma
Published on 2 Sep 2021
Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with relapsed/ refractory B-ALL in Journal of Clinical Oncology
Published on 1 Sep 2021
TCR² therapeutics announces renowned translational medicine leader Priti Hegde joins its board of directors
Published on 26 Aug 2021
Philippe Deecke appointed as Chief Financial Officer of Lonza Group
Published on 26 Aug 2021
MHRA grants AKL Research and Development (AKLRD) an Innovation Passport for APPA in Osteoarthritis
Published on 23 Aug 2021
Autolus Therapeutics Announces Promising Innovative Medicine (PIM) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL
Published on 9 Aug 2021
Autolus and Moderna sign Option and License Agreement for access to proprietary targeting technology from Autolus
Published on 2 Aug 2021
Revolo Biotherapeutics Announces Clinical Trial Authorization to Initiate Phase 2 Trial of ‘1104 in Allergic Disease in the UK
Published on 30 Jul 2021
Cell and Gene Therapy Catapult - Innovative gene therapy programme paves the way for new treatments for neurodegenerative diseases
Published on 29 Jul 2021
Cytiva and Pall Corporation investing 1.5 billion USD over two years to meet growing demand for biotechnology solutions
Published on 27 Jul 2021
GSK unveils plan for one of Europe’s largest life science campuses in Stevenage
Published on 16 Jul 2021

Copyright © 2021 Stevenage Bioscience Catalyst

Designed and built by Onespacemedia

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.